Compare AstraZeneca plc (AZN) vs DraftKings Inc (DKNG) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

DraftKings (DKNG) trades at $24.27, up 1.0% today, showing mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company achieved its first annual net profit in 2025 ($4M) after years of losses, with revenue growing to $6.05B. However, recent quarterly earnings have missed expectations, and valuation ratios remain elevated with a P/E of 246.33. Analyst sentiment remains positive with 73% buy ratings and a $34 consensus price target, representing 40% upside potential.

The outlook for DKNG hinges on successful execution in prediction markets and sportsbook growth, particularly with the upcoming NFL season. Key risks include intense competition from prediction market platforms, regulatory challenges, and the company's ability to maintain profitability after recently turning profitable. While technical indicators show near-term resistance at $25, the substantial analyst upside and improving cash flow trends suggest potential for long-term growth if execution improves.